Abstract
Background
HCC is a common cancer worldwide and one of the leading causes of cancer death. This aim of this study is to determine the age and gender characteristics of the HCC patients in our center and to determine the contribution of viral hepatitis (B and C) and alcohol to the etiology of HCC among our patients.
Methodology
This is a retrospective study of HCC patients seen at the gastroenterology unit of ABUTH between April 2015 and September 2018. Data on age, gender, HBsAg, and HCV antibody status and alcohol consumption were recorded from the case files of all eligible patients.
Results
A total of 87 patients were included in the study. They consisted of 68 males (78.2%) and 19 females (21.8%) with male to female ratio of 4:1. The mean age of the study subjects was 46.7 years (SD ± 12.5), with a range of 22 and maximum age of 80 years. Majority of the patients were within the age group 40-49 (32.2%). HBsAg was present in 48 patients (55.2%), HCV antibody was positive in 14 patients (16.1%) and 3 patients (3.4%) were positive for both HBsAg and HCV antibody. Four (4.6%) had significant alcohol ingestion and in 18 patients (20.7%), the etiology was undetermined.
Conclusion
In our study, HCC was found predominantly among male patients in the age group 40-49 years. Viral hepatitis particularly HBV is the most important etiological factor for HCC among our patients.
Keywords: Age, Sex, Hepatitis B and C, Alcohol, Primary Liver Cell Carcinoma
Introduction
Primary liver cell carcinoma(PLCC) is a disease of public health concern with increasing incidence globally.[1] The most common form of PLCC is hepatocellular carcinoma(HCC) and the terms are commonly used interchangeably[2]In 2020, PLCC was estimated to be 7th most commonly diagnosed cancer world-wide and the 3rdmost common cause of cancer mortalitiy.[3] Incidence of liver cancer varies around the world and traditionally more common in developing countries. It is estimated to be the 4th leading cancer in Africa and ranks highest among men in several West African countries. [4] Hepatocellular carcinoma (HCC) is the 2nd commonest cause of cancer death among men, and 3rd among women in Africa.[5] The high rate of liver cancer in these countries reflects the prevalent causative factors of this carcinoma in these countries particularly chronic hepatitis B infection. In Nigeria, there is paucity of data on the incidence PLCC. According to WHO in 2018, it was estimated that 5,129 new cases with similar number of deaths will be recorded that year in Nigeria.[6] Fakunle et al reported more than 4 decades ago that Zaria has one of the highest burdens of PLCC in the world.[7] Whether this is still the case is difficult to say as there is no recent report on PLCC from Zaria. Liver cancer is more common among males with male to female ratio of up to 4:1. [8,9] The age at which patient present varies across regions of the world. In Europe the median age of presentation is 65years while in sub-Saharan Africa, it is 45years.[5] This variation in age at presentation reflects the predominant risk factors for HCC across different regions of the world. In several parts of Africa and Asia where HBV is the predominant risk factor, the age at presentation is much lower compared to the developed countries where HCV and more recently NAFLD are the predominant risk factors for HCC.[10-12] Hepatocellular carcinoma(HCC) is the most common form of PLCC accounting for 70% to 85% of PLCC.[13] Most HCC occur on a background of liver cirrhosis.[13-15]Hepatitis B and C viruses are the most common risk factors for HCC with the most significant being HBV.[16-18]Cirrhosis from these viruses carries higher risk of HCC compared to other causes of cirrhosis.[13,19]Other etiological factors of HCC include alcohol, Non-Alcoholic Fatty Liver Disease(NAFLD), aflatoxin B1, and iron overload.[8,20-22]NAFLD is particularly important in that it is now assuming the most common cause of liver disease worldwide and has been associated with HCC even without cirrhosis.[,24]Additionally, HCC hitherto classified as idiopathic in significant number of cases can be associated with NAFLD.[21]
This article sought to examine the demographic profile namely the age and gender distribution of HCC patients in our Centre, and then determine the contribution of viral hepatitis B and C and alcohol to the etiology of HCC among our patients.
Methodology
This is a retrospective study of all adult patients seen at the gastroenterology unit of Ahmadu Bello University Teaching Hospital between April 2015 and September 2018 with diagnoses of HCC.
Data on age, sex, and presence or absence of HBsAg, HCV antibody and significant alcohol consumption were recorded from the case file of all eligible patients. Alcohol consumption of at least 60g/day in males and 20g/day in female patients for at least 10 years is considered significant. Eligible patients are those with the clinical diagnosis of HCC and have at least one of the following: 1-imaging (ultrasound/CT scan) findings of HCC and 2- histologic features of HCC.
Data was analyzed using statistical software IBM SPSS Version 23. Results from categorical data were expressed as frequencies and percentages, while quantitative data were expressed as mean and standard deviation and presented as tables.
Results
Demographic characteristics
A total of 87 patients were eligible and included in the study. They consisted of 68 males (78.2%) and 19 females (21.8%) with male to female ratio of 4:1. The mean age of the study subjects was 46.7 years (SD ± 12.5), ranging from a minimum age of 22 to a maximum age of 80. Majority of the patients were within the age group 40-49 years (32.2%) with only 4 patients aged 70 and above. (Table 1)
Table 1:
Age and gender distribution of patients
GENDER | |||
---|---|---|---|
AGE GROUP | MALE(n) | FEMALE (n) | TOTAL (n) |
20-29 | 4 | 1 | 5 |
30-39 | 16 | 3 | 19 |
40-49 | 23 | 5 | 28 |
50-59 | 12 | 6 | 18 |
60-69 | 11 | 2 | 13 |
>70 | 2 | 2 | 4 |
TOTAL | 68 | 19 | 87 |
FREQUENCY | PERCENTAGE | ||
HBV | 48 | 55.2 | |
HCV | 14 | 16.1 | |
HBV+HCV | 3 | 3.4 | |
ALCOHOL | 4 | 4.6 | |
UNDETERMINED | 18 | 20.7 | |
TOTAL | 87 | 100.0 |
Etiology of HCC
HBsAg only was present in 48 patients (55.2%), HCV antibody was positive in 14 patients (16.1%) and 3 patients (3.4%) were positive for both HBsAg and HCV antibody. Four (4.6%) had significant alcohol ingestion and 18 patients (20.7%) had none of these three etiological factors. (Table 2).
Discussion
HCC is a common malignancy and one of the leading causes of cancer mortality worldwide. Majority of our patients are males with a male to female ratio of 4:1. This is consistent with other findings in Nigeria and other countries.[25-27]Most of our patients fall within the age group of 40-49 years with the mean age of presentation being 46.7±12.5 similar to findings by others in Nigeria.[25,26,28] Prevalence peaked at age 40-49 years and decreases with advancing age among our patients. Kew et al reported decreasing incidence with increasing age among rural black population with HCC, however, incidence generally increases with increasing age. [26,29]
HBV is the single most important risk factor for HCC.[30] It is hyperendemic in most parts of Africa and in Nigeria pooled prevalence wass9.5%in a systematic review and metanalysis by Ajuwon et al. [,32] In our study, 55.2% of the patients were positive for HBsAg. This frequency of HBsAg seropositivity among our patients agrees with findings by Nwokediuko et al in Enugu and Mustapha et al in Gombe. [28,33] Similar finding was also reported by Chin'ombe et al in Zimbabawe and Umoh et al in The Gambia. [35] This finding indicate that HBV is the most important risk factor for HCC in our patients. HCV antibody on the other hand was found in 16.1% of our patient. This is similar to findings by other authors in Nigeria and The Gambia[25,28,35-37]Both HBV and HCV constituted about 75% of the risk factors for HCC among our patients which is in consonance with the report of 75-80% of HCC worldwide are attributable to chronic HBV and HCV infections.[16,35,38]Co-infection with these viruses was not common among our patients and found in only 3.4% of the patients similar to finding by Krik et al in The Gambia and Ayoola et al in Saudi Arabia.[37,39] However, dual infection confers increased risk of HCC development on the patients.[37]The contribution of alcohol to the etiology of HCC among our patient is substantially less as significant alcohol ingestion was found in only 4.6% of the patients. This is consistent with the fact that alcohol play a minor role in the etiology of HCC compared to viral hepatitis particularly in intermediate and high incidence areas such as ours. [27,40,41]
Significant number of our patients (20.7%) don't have evidence of viral hepatitis B and C or history of significant alcohol ingestion. Other etiological factors of HCC may be responsible in these categories of patients. Though exposure to aflatoxin was not tested for among our patients, it is possible that these patients with undetermined risk factors have aflatoxin as their major risk. Aflatoxin exposure is an important risk factor for HCC in regions of the world where HBV is endemic such as sub-Saharan Africa.[29,42] Aflatoxin is a hepatocarcinogen found in many staple food products in parts of the world such as sub-Saharan Africa where poor food storage practice, high humidity and temperature allows the growth of the fungus Aspergillus spp.[43-46]NAFLD has become the most common cause of liver disease worldwide and is associated with obesity and metabolic syndrome.[47-50] And because of our increasing rate of adoption of western lifestyle, it is expected that NAFLD will also increase among our populace with the attendant consequences such as cirrhosis and HCC. Therefore, NAFLD may be a contributing factor to etiology of HCC among our patients. Further studies are needed to elucidate the actual contributions of these other factors to the etiology of HCC among patients.
In conclusion, PLCC among our patients commonly affect male patients in the age group 40-49 years. Viral hepatitis particularly HBV is the most important etiological factor and together with alcohol accounted for about 80% of the causes of PLCC among our patients.
References
- 1.Njei B, Rotman Y, Ditah I, Lim JK. Emerging. Trends in Hepatocellular Carcinoma Incidence and Mortality. Hepatology 2014; 00: 1-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010; 42(suppl 3): S206-S214. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A cancer journal for clinicicans. 2021;71:209-249. [DOI] [PubMed] [Google Scholar]
- 4.Parkin DM, Bray F, Ferlay J, Jemal A. Cancer in Africa 2012. Cancer epidemiol Biomarkers Prev. 2014; 23: 953-66. [DOI] [PubMed] [Google Scholar]
- 5.Thursz MR. Field battle against hepatitis B infection and HCC in Africa. J Hepatol. 2016; 1-27 [DOI] [PubMed] [Google Scholar]
- 6.WHO. Nigeria: Fact sheet. Global Cancer observatory. International agency for research on cancer, World Health Organisation (WHO), May 2019. Available at http://gco.iarc.fr/today/data/factsheets/populations/566-nigeria-fact-sheet.pdf, accessed on 14/01/2020 by 22:06pm.
- 7.Fakunle YM, Ajdukiewicz AB, Greenwood BM, Edington GM. Primary liver cell carcinoma (PLCC) in the Northern Guinea Savanna of Nigeria. Vol. 71, Transactions of the Royal Society of Tropical Medicine and Hygiene. 1977;71:335-337 [DOI] [PubMed] [Google Scholar]
- 8.Okeke E, Davwar PM, Roberts L, Sartorius K, Spearman W, Malu A, et al. Epidemiology of Liver Cancer in Africa: Current and Future Trends. Semin Liver Dis 2019; 1-13 [DOI] [PubMed] [Google Scholar]
- 9.Sartorius K, Sartorius B, Aldous C, Govender PS, Madiba TE. Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications. Cancer Epidemiology. 2015; 39: 284-290. [DOI] [PubMed] [Google Scholar]
- 10.Gao J, Xie L, Yang W-S, Zhang W, Gao S, Wang J et al. Risk Factors of Hepatocellular Carcinoma-Current Status and Perspectives. Asian Pacific J Cancer Prev. 2012; 13: 743-752. [DOI] [PubMed] [Google Scholar]
- 11.Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019; 380: 1450-62 [DOI] [PubMed] [Google Scholar]
- 12.Lucas C, Lucas G, Lucas N, Krzowska-Firych J, Tomasiewicz K. A Systematic Review of the Present and Future of Non-Alcoholic Fatty Liver Disease. Clin Exp Hepatol. 2018; 4: 165-174. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of Hepatology. 2006; 45: 529-538. [DOI] [PubMed] [Google Scholar]
- 14.Balogh J, Victor D, Asham EH, Burroughs SG, Boktour M, Saharia A, et al. Hepatocellular carcinoma: a review. Journal of Hepatocellular Carcinoma. 2016; 3: 41-53. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Flores A, Marrero JA. Emerging Trends in Hepatocellular Carcinoma: Focus on Diagnosis and Therapeutics. Oncology 2014; 8: 71-76 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Liu C-J, Kao J-H. Hepatitis B Virus-related Hepatocellular Carcinoma: Epidemiology and Pathogenic Role of Viral Factors. Vol. 70, J Chin Med Assoc. 2007; 70: 141-145. [DOI] [PubMed] [Google Scholar]
- 17.Beasley RP. Hepatitis B Virus the Major Etiology of Hepatocellular Carcinoma. Cancer 1988; 61:1942-1956. [DOI] [PubMed] [Google Scholar]
- 18.Sherman M, Llovet JM. Smoking, Hepatitis B Virus Infection, and Development of Hepatocellular Carcinoma. Journal of the National Cancer Institute 2011; 103: 1642-1643. [DOI] [PubMed] [Google Scholar]
- 19.Bialecki ES, Di Bisceglie AM. Clinical presentation and natural course of hepatocellular carcinoma. Eur J of Gastroenterol & Hepatol. 2005; 17: 485-489. [DOI] [PubMed] [Google Scholar]
- 20.Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357. [DOI] [PubMed] [Google Scholar]
- 21.Kikuchi L, Oliveira CP, Carrilho FJ. Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. BioMed Research International vol. 2014; Article ID 106247, 6 pages, 10.1155/2014/106247 [DOI] [PMC free article] [PubMed]
- 22.Tu QV, Okoli AS, Kovach Z, Mendz. Hepatocellular carcinoma: prevalence and molecular pathogenesis of Helicobacter spp. Future Microbiol. 2009; 4: 1283-1301. [DOI] [PubMed] [Google Scholar]
- 23.D'Avola D, Labgaa I, Villanueva A. Natural History of Nonalcoholic Steatohepatitis/Nonalcoholic Fatty Liver Disease-Hepatocellular Carcinoma: Magnitude of the Problem from a Hepatology clinic Perspective. Clinical Liver Disease 2016; 8: 100-104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Pennisi G, Celsa C, Giammanco A, Spatola F, Petta S. Molecular Sciences the Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. Int J Mol Sci. 2019; 20: 1-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Mustapha S, Bolori M, Ajayi N, Nggada H, Pindiga U, Gashau W, et al. Hepatocellular Carcinoma In North-Eastern Nigeria: A Prospective Clinical Study Of 100 Cases. The Internet Journal of Gastroenterology 2006;6: 1-5 [Google Scholar]
- 26.Kew MC. Epidemiology of hepatocellular carcinoma in sub-Saharan Africa. Annals of Hepatology. 2012; 12:173-182. [PubMed] [Google Scholar]
- 27.Mcglynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015; 19:223-238. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Nwokediuko SC, Ijoma UN, Obienu O. Liver Cancer in Enugu, South East Nigeria. Insight Bioinformatics 2011; 1: 1-5. [Google Scholar]
- 29.Leong TY-M, Leong AS-Y. Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB 2005; 7: 5-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Béguelin C, Fall F, Seydi M, Wandeler G. Expert Review of Gastroenterology & Hepatology The current situation and challenges of screening for and treating hepatitis B in sub-Saharan Africa the current situation and challenges of screening for and treating hepatitis B in sub-Saharan Africa. Expert Review of Gastroenterology and Hepatology 2018; [DOI] [PubMed] [Google Scholar]
- 31.Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best Practice and Research Clinical Gastroenterology 2008; 22: 991-1008. [DOI] [PubMed] [Google Scholar]
- 32.Ajuwon BI, Yujuico I, Roper K, Richardson A, Sheel M, and Lidbury BA. Hepatitis B virus infection in Nigeria: a systematic review and meta-analysis of data published between 2010 and 2019. BMC infect 2021; 21:1120. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Mustapha SK, Pindiga UH. The Prevalence of Hepatitis B Virus in Patients with Hepatocellular Carcinoma in Gombe, North Eastern Nigeria. Sahel Medical Journal 2003; 6:104-106. [Google Scholar]
- 34.Chin'ombe N, Chavhunduka E, Matarira HT. Seroprevalence of HBV and HCV in primary hepatocellular carcinoma patients in Zimbabwe. Infectious Agents and Cancer 2009; 4:15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Umoh NJ, Lesi OA, Mendy M, Bah E, Akano A, Whittle H, et al. Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia. [DOI] [PubMed] [Google Scholar]
- 36.Mustapha S, Bolori M, Ajayi N, Nggada H, Pindiga U, Gashau W, et al. Hepatitis C Virus Antibodies In Nigerians With Hepatocellular Carcinoma. The Internet Journal of Oncology. 2006; 4: 4 [Google Scholar]
- 37.Kirk GD, Lesi OA, Mendy M, Akano AO, Sam O, Goedert JJ, et al. The Gambia Liver Cancer Study: Infection with Hepatitis B and C and the Risk of Hepatocellular Carcinoma in West Africa. Hepatology 2004; 39: 211-219. [DOI] [PubMed] [Google Scholar]
- 38.Bosch FX, Ribes J, Díaz M, Cléries R. Primary Liver Cancer: Worldwide Incidence and Trends. Gastroenterology 2004; 127: S5-S16. [DOI] [PubMed] [Google Scholar]
- 39.Ayoola EA, Gadour MO. Hepatocellular carcinoma in Saudi Arabia: Role of hepatitis B and C infection. J Gastroenterol Hepatol. 2004;19:665–669. [DOI] [PubMed] [Google Scholar]
- 40.Zidan A, Scheuerlein H, Schüle S, Settmacher U, Rauchfuss F. Epidemiological Pattern of Hepatitis B and Hepatitis C as Etiological Agents for Hepatocellular Carcinoma in Iran and Worldwide. Hepatitis Monthly, 12(10 HCC), e6894. doi: 10.5812/hepatmon.68 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Mohamed AE, Kew MC, Groeneveld HT. Alcohol Consumption as a Risk Factor for HEepatocellular Carcinoma in Urban Southern African Blacks. Int J Cancer 1992; 51: 537-541. [DOI] [PubMed] [Google Scholar]
- 42.Kew MC, Kew MC. Synergistic interaction between aflatoxin B 1 and hepatitis B virus in hepatocarcinogenesis. Liver International 2003; 23: 405-409. [DOI] [PubMed] [Google Scholar]
- 43.Wang J-S, Tang L. Epidemiology of Aflatoxin Exposure and Human Liver Cancer. Article in Toxin Reviews 2008; 195-211. Doi: 10.1081/TXR-200027834. [DOI] [Google Scholar]
- 44.Hamid AS, Tesfamariam IG, Zhang Y, Zhang ZG. Aflatoxin B1-induced Hepatocellular Carcinoma in Developing Countries: Geographical Distribution, Mechanism of Action and Prevention (Review). Oncology Letters 2013; 5: 1087-1092. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Vhriterhire RA. Aflatoxin Contribution to Liver Cancer Burden in Nigeria: A Mini Review. Jos Journal of Medicine; 10: 29-32 [Google Scholar]
- 46.Anthony MH, Francis DM, Berka NP, Ayinla GT, Haruna OG. Aflatoxin Contamination in Foods and Feeds: A Special Focus on Africa. Trends in Vital Food and Control Engineering; 187-234. [Google Scholar]
- 47.Rinella ME. Nonalcoholic Fatty Liver Disease A Systematic Review. JAMA. 2015; 313: 2263-2273. [DOI] [PubMed] [Google Scholar]
- 48.Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2008; 53: 362-376. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Diehl AM, Day C. Causes, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. N Eng J Med. 2017;377:2063-2072. [DOI] [PubMed] [Google Scholar]
- 50.Yu BC-Y, Kwok D, Wong VW-S. Magnitude of Nonalcoholic Fatty liver disease: Eastern Perspective. J of Clin Exp Hepatol. 2019; 9: 491-496. [DOI] [PMC free article] [PubMed] [Google Scholar]